We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals

By LabMedica International staff writers
Posted on 13 Dec 2024

A complete blood count (CBC) screening is a standard examination most physicians request for healthy adults. More...

This test is essential for evaluating a patient’s overall health with a single blood sample. Currently, CBC results are interpreted using a universal reference interval, but a new study suggests this approach may overlook critical health deviations. The study, published in Nature, found that these reference intervals, or setpoints, are individualized and that one healthy patient’s CBC setpoints can differ from 98% of other healthy adults.

While CBC indices can change due to factors like genetics, medical history, and age, this new study, led by researchers from Mass General Brigham (Somerville, MA, USA), suggests that each patient has a specific “setpoint”—a baseline value around which measurements naturally fluctuate. By considering these personalized CBC setpoints, doctors could identify early-stage diseases in otherwise healthy adults, such as diabetes, heart disease, and kidney failure, which could greatly benefit from early detection and intervention.

The study demonstrated that setpoints offer a two- to four-fold relative risk stratification for several diseases, comparable to that of conventional screening methods. The researchers highlight that this discovery opens new avenues for studying how CBC thresholds vary among individuals. Additionally, the information from CBC setpoints could be used to design more targeted treatment plans and help determine whether further screening is necessary for accurate diagnosis.

“Complete blood counts are common tests, and our study suggests CBCs vary a lot from person to person even when completely healthy, and a more personalized and precision medicine approach could give more insight into a person’s health or disease,” said senior author John Higgins, MD, of the Center for Systems Biology and Department of Pathology at Massachusetts General Hospital. “The long-term stability and patient-specificity of setpoints may provide new opportunities for the personalized management of healthy adults envisioned by precision medicine.”


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Multilevel Whole Blood Calibrator Set
6PLUS1
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.